Neochem Bio Solutions Delivers Strong FY26 Growth With Expanding Margins
Neochem Bio Solutions Ltd · Intimation · 23 Sept 2026, 9:05 pm
Neochem Bio Solutions Delivers Strong FY26 Growth With Expanding Margins Neochem Bio Solutions reported FY26 revenue from operations of ₹110.7 crore, up 32% YoY (35% 2-year CAGR), driven by domestic strength and expanding end-market applications. EBITDA surged 53% YoY to ₹22.6 crore with margins expanding 321 bps YoY to 20.4%, while PAT jumped 62% YoY to ₹12.0 crore. Capacity utilization at its 22,000 MTPA Ahmedabad plant rose to 52.7% from 41.8% in FY25. The company deleveraged significantly, reducing its net debt-to-equity ratio to 0.2x following its ₹42.7 crore IPO on NSE SME.
Original exchange filing (PDF)
More announcements from Neochem Bio Solutions Ltd
- Neochem Bio Solutions Limited has informed the Exchange about Transcript · 03 Nov 2026
- Neochem Bio Solutions Limited has informed the Exchange about Link of Recording · 30 Oct 2026
- Neochem Bio Solutions Limited has informed the Exchange about Investor Presentation · 29 Oct 2026
- Neochem Bio Solutions Limited has submitted to the Exchange, the Unaudited Half Yearly financial results for the period ended September 30, 2026. · 28 Oct 2026
- Neochem Bio Solutions Limited has informed the Exchange about Schedule of meet · 27 Oct 2026
- NEOCHEM BIO SOLUTIONS LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 27 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 27 Oct 2026
- Neochem Bio Solutions has submitted Statement of Investor Grievances under Reg. 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 30th September, 2026. · 20 Oct 2026
